DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.

Author(s): Castaneda CA, Gomez HL

Affiliation(s): Division of Medicine, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, Lima 34, Peru.

Publication date & source: 2009-06, Nat Rev Clin Oncol., 6(6):308-9.

Publication type: Comment

A randomized phase III trial evaluated the effect of adding lapatinib to paclitaxel as first-line therapy for patients with metastatic breast cancer whose tumors were negative or untested for human epidermal growth factor receptor 2 (HER2) overexpression. Progression-free survival was prolonged significantly in patients with HER2-overexpressing tumors, which indicates that lapatinib exerts its main effects via the HER2 pathway.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017